Laliberte Kevin 4
4 · Dova Pharmaceuticals, Inc. · Filed Mar 14, 2018
Insider Transaction Report
Form 4
Laliberte Kevin
Sr. VP, Product Development
Transactions
- Award
Stock Option (right to buy)
2018-03-12+50,000→ 50,000 totalExercise: $29.33Exp: 2028-03-11→ Common Stock (50,000 underlying)
Footnotes (1)
- [F1]One-fourth of the shares underlying this option vest on March 12, 2019 and the balance of the shares vest in a series of 36 successive equal monthly installments thereafter, subject to the reporting person's continuous service as of each such vesting date.